Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬ £¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

´ÓÖ×ÁöɱÈë×ÔÃ⣡Æë³Èý¿¹ÐÂÒ©ÔٴλñÅúÁÙ´² | 1·ÖÖÓÒ©ÎÅËÙÀÀ

2025-05-06
|
»á¼ûÁ¿£º

0507.jpgÒ½ÏßÒ©ÎÅ

1. 5ÔÂ6ÈÕ£¬£¬£¬ £¬£¬CDE ¹ÙÍøÏÔʾ£¬£¬£¬ £¬£¬ÆëÂ³ÖÆÒ©×¢ÉäÓà QLS4131 »ñÅúÁÙ´²£¬£¬£¬ £¬£¬ÓÃÓÚϵͳÐÔºì°ßÀÇ´¯¡£¡£¡£QLS4131 ÊÇÒ»¿î BCMA/GPRC5D/CD3 Èý¿¹¡£¡£¡£¸ÃÒ©×îÔçÓÚ24Äê5ÔÂÔÚÖйúÉêÇëÁÙ´²£¬£¬£¬ £¬£¬24Äê7ÔÂÊ״λñÅúÁÙ´²£¬£¬£¬ £¬£¬ÄâÓÃÓÚ¶à·¢ÐÔ¹ÇËèÁö¡£¡£¡£

2. 5ÔÂ6ÈÕ£¬£¬£¬ £¬£¬°¢Ë¹Àû¿µÐû²¼£¬£¬£¬ £¬£¬°¢¿ÉÌæÄáÓë±½´ïĪ˾͡ºÍÀûÍ×Îôµ¥¿¹ÁªºÏʹÓÃÒÑÔÚÅ·ÃË»ñµÃÅú×¼£¬£¬£¬ £¬£¬ÓÃÓÚÖÎÁÆÎ´½ÓÊܹýÖÎÁÆÇÒ²»ÊʺϽÓÊÜ×ÔÌå¸Éϸ°ûÒÆÖ²µÄÌ×ϸ°ûÁܰÍÁö£¨MCL£©³ÉÄ껼Õß¡£¡£¡£ÐÂΟåÖ¸³ö£¬£¬£¬ £¬£¬ÕâÊÇÅ·ÃËÊ׸öÒ²ÊÇΨÖðÒ»¸ö»ñÅúÓÃÓÚ¸Ã˳Ӧ֢µÄ BTK ÒÖÖÆ¼Á¡£¡£¡£

3. 5ÔÂ6ÈÕ£¬£¬£¬ £¬£¬CDE¹ÙÍøÏÔʾ£¬£¬£¬ £¬£¬Ã÷»ÛÒ½Ò©£¨º¼ÖÝ£©ÓÐÏÞ¹«Ë¾ÁªºÏÉêÇëÒ©Æ·¡°×¢ÉäÓÃMHB046C¡±£¬£¬£¬ £¬£¬»ñµÃÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬£¬ £¬£¬Ë³Ó¦Ö¢£ºÓÃÓÚÖÎÁÆÍíÆÚʵÌåÁö»¼Õß¡£¡£¡£

4. 5ÔÂ6ÈÕ£¬£¬£¬ £¬£¬CDE¹ÙÍøÏÔʾ£¬£¬£¬ £¬£¬ÄϾ©Ê¥ºÍÒ©Òµ¹É·ÝÓÐÏÞ¹«Ë¾ÁªºÏÉêÇëÒ©Æ·¡°SH009×¢ÉäÒº¡±£¬£¬£¬ £¬£¬»ñµÃÁÙ´²ÊÔÑéĬʾÔÊÐí¡£¡£¡£SH009×¢ÉäÒºÊÇÄϾ©Ê¥ºÍÒ©Òµ×ÔÖ÷Ñз¢µÄPD-L1/CD47Ë«¿¹Ò©Î£¬£¬ £¬£¬Ë³Ó¦Ö¢£º±¾Æ·ÁªºÏ»¯ÁÆÓÃÓÚÍíÆÚ·ÇСϸ°û·Î°©µÄÖÎÁÆ¡£¡£¡£

ͶÈÚÒ©ÊÂ

1. ¿ËÈÕ£¬£¬£¬ £¬£¬Ä¬É³¶«Ðû²¼£¬£¬£¬ £¬£¬Î»ÓÚÌØÀ­»ªÖÝÍþ¶ûÃ÷¶ÙÊмÛÖµ10ÒÚÃÀÔª¡¢Õ¼µØ47Íòƽ·½Ó¢³ßµÄÐÂÉúÎïÖÆ¼Á׿ԽÖÐÐÄÒÑ×îÏȽ¨Éè¡£¡£¡£¾Ý¹«Ë¾³Æ£¬£¬£¬ £¬£¬Ð¹¤³§½«´´Á¢500¸öȫְ¸Ú룬£¬£¬ £¬£¬Ô¤¼Æ½«Ö§³ÖÏÂÒ»´úÉúÎïÖÆ¼ÁÉú²ú£¬£¬£¬ £¬£¬°üÀ¨¿¹Ìå-Ò©ÎïżÁªÎ£¬£¬ £¬£¬ÒÔ¼°³ÉΪδÀ´ÃÀ¹úKeytruda£¨ÅÁ²©ÀûÖéµ¥¿¹£©µÄÖÆÔìÖÐÐÄ¡£¡£¡£

¿Æ¼¼Ò©ÑÐ

1. 5ÔÂ1ÈÕ£¬£¬£¬ £¬£¬¸£½¨Ê¡Ò©ÎïаеãÑо¿ÖصãʵÑéÊÒ¡¢ÏÃÃÅ´óѧҩѧԺÁõÎĽÌÊÚÍŶÓ£¬£¬£¬ £¬£¬ÁªºÏÏÃÃÅ´óѧ¹«¹²ÎÀÉúѧԺÏÄÄþÉÛԺʿºÍÂÞÎÄнÌÊÚÍŶÓ£¬£¬£¬ £¬£¬ÓÚ Nature Cancer  ÆÚ¿¯½ÒÏþÌâΪ  PILR¦Á on tumor cells interacts with the T cell surface protein CD99 to suppress antitumor immunity  µÄÍ»ÆÆÐÔÑо¿Ð§¹û£¬£¬£¬ £¬£¬Ê×´ÎÕ¹ÏÖÁËÖ×Áöϸ°ûÍâò±í´ïµÄÅä¶ÔÃâÒßÇòÂѰ×Ñù2ÐÍÊÜÌå¦Á£¨PILR¦Á£©×÷ΪһÖÖÐÂÐÍÃâÒß¼ì²éµã£¬£¬£¬ £¬£¬Í¨¹ý°ÐÏòTϸ°ûÍâòµÄCD99·Ö×ÓÔö½øÖ×ÁöÃâÒßÌÓÒݵÄлúÖÆ£¬£¬£¬ £¬£¬²¢¿ª·¢³ö°ÐÏòPILR¦ÁµÄÖÎÁÆÐÔ¿¹Ì壬£¬£¬ £¬£¬ÎªÍ»ÆÆÄ¿½ñ°©Ö¢ÃâÒßÖÎÁÆÆ¿¾±ÌṩÁËȫвßÂÔ¡£¡£¡£ 

[1]Xia, L., Liu, Jy., Yu, C. et al. PILR¦Á on tumor cells interacts with the T cell surface protein CD99 to suppress antitumor immunity. Nat Cancer (2025). https://doi.org/10.1038/s43018-025-00958-7

Ïà¹ØÐÂÎÅ
ijÑо¿Ëù·¢Ã÷ÖÎÁƶ෢ÐÔ¹ÇËèÁöµÄÖÎÁÆÐ°еã
2016-08-15
ÈÕǰ£¬£¬£¬ £¬£¬°Ä´óÀûÑÇÎÖ¶ûÌØÓëÒÁÀöɯ»ô¶ûҽѧÑо¿Ëù(Walter and Eliza Hall Institute of Medical Research)µÄÑо¿Ö°Ô±·¢Ã÷ÁËÖÎÁƶ෢ÐÔ¹ÇËèÁöµÄÖÎÁÆÐ°еã¡£¡£¡£ËûÃÇ·¢Ã÷£¬£¬£¬ £¬£¬´ó´ó¶¼¹ÇËèÁöÐèÒªÒÀÀµMCL-1ÂѰ×À´Î¬³Öϸ°ûÉúÑÄ¡£¡£¡£
FDAÒÑÊÚÓèDaratumumabÖÎÁƶ෢ÐÔ¹ÇËèÁö£¨MM£©µÄ¹Â¶ùҩְλ
2015-11-18
¿ËÈÕ£¬£¬£¬ £¬£¬Ê׸öµ¥¿Ë¡¿¹ÌåÒ©ÎïdaratumumabÒѱ»ÃÀ¹úʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨FDA£©Åú×¼ÓÃÓÚÖÎÁƶ෢ÐÔ¹ÇËèÁö£¨MM£©¡£¡£¡£¹ØÓÚ¾­ÖÁÉÙ3ÖÖÁÆ·¨ÖÎÁƵϼÕßÀ´Ëµ£¬£¬£¬ £¬£¬¸ÃÒ©ÊÇÒ»ÖÖ¼«¼ÑµÄÖÎÁÆÑ¡Ôñ¡£¡£¡£
2023ÄêÐÂÐÍÖØ°õÒ©Îォ°Ñ¶à·¢ÐÔ¹ÇËèÁöÁÆ·¨Êг¡ÍÆÖÁ224ÒÚÃÀÔª
2015-11-06
GlobalDataÔÚ×î½üµÄһƪ±¨¸æÖÐÖ¸³ö£¬£¬£¬ £¬£¬È«Çò¶à·¢ÐÔ¹ÇËèÁöÁÆ·¨Êг¡µÄÔöÌí½«·ºÆðÔÚÒÔÏÂ8¸öÖ÷Òª¹ú¼ÒÖУ¬£¬£¬ £¬£¬¼´ÃÀ¹ú¡¢·¨¹ú¡¢µÂ¹ú¡¢Òâ´óÀû¡¢Î÷°àÑÀ¡¢Ó¢¹ú¡¢ÈÕ±¾¡¢Öйú¡£¡£¡£´Ó2014ÄêÖÁ2023Äê´Ë10Äêʱ¼äÄÚ£¬£¬£¬ £¬£¬¸ÃÖÎÁÆÁìÓòµÄ¸ßËÙÔöÌíÓÉÒ»Ö±ÎÊÊÀµÄÐÂÁÆ·¨ËùÇý¶¯£¬£¬£¬ £¬£¬°üÀ¨2ÖÖ¾ßÓкܴóDZÁ¦µÄµ¥¿Ë¡¿¹Ì壨mAbs£©£¬£¬£¬ £¬£¬¼´Empliciti¼°Daratumumab¡£¡£¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿